Optimistic about the prospects of the core drug Obefazimod, investment bank Guggenheim gives AbiVax (ABVX.US) a “buy” rating

The Zhitong Finance App learned that before French biotech company Abivax (ABVX.US) released data on its core drug obefazimod, the investment bank Guggenheim raised the company's target share price from $150 to $175 and gave it a “buy” rating.

Analyst Yatin Suneja said the adjustment was based on the optimistic outlook for the 44th week maintenance period data for its core drug, obefazimod, which will be released soon.

On December 15, Abivax announced financial results for the third quarter of 2025. The company's revenue was $2.4 million, exceeding market expectations by $1.06 million. However, losses per share totaled $1.68 for the quarter. The company's net loss for the first nine months increased to €254.1 million, up from €136.9 million for the same period in 2024. The company's financial activity reflects a growing focus on its main drug candidate, Obefazimod, the first of its kind oral miR-124 enhancer.

R&D expenses increased to 133.4 million euros, mainly driven by progress in the ABTECT phase III project for ulcerative colitis and the ENHANCE-CD phase IIb trial for Crohn's disease. Abivax is preparing for several important milestones in 2026. The main results of the ABTECT maintenance trial are expected to be announced in the second quarter of 2026, which will provide the final clinical basis for planning to submit a new drug application to the US FDA in the second half of 2026.